Take Action: Tell your senators to reject harmful cuts to health care!
Prescription Drugs
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Negotiated Prices Take Effect for Ten Drugs in 2026
October 9, 2025
The Inflation Reduction Act (IRA) of 2022 created a new ability for Medicare to negotiate prices for the most expensive
Part D Benefit Restructuring Reduces Out-Of-Pocket Exposure, Changes Risk to Prescription Coverage Access and Choice
July 17, 2025
Prescription drug coverage in Medicare, provided via private health insurance plans under Part D, covers more than 53 million Americans.
New Research Confirms Importance of Drug Affordability and Low Out-of-Pocket Costs
April 24, 2025
As we have highlighted in past articles, many people with Medicare—and many callers to our national consumer helpline—struggle to afford
Drug Pricing Executive Order Boosts Pharmaceutical Industry’s Goals
April 17, 2025
On Tuesday, President Trump issued an executive order on prescription drug pricing that supports key drug industry efforts to weaken
Proposed Rule Would Improve Medicare Advantage Prior Authorization and Transparency
January 30, 2025
This week, Medicare Rights submitted comments in response to the annual Medicare Advantage (MA) and Part D proposed rule for
Comments on Proposed 2026 Medicare Advantage Part D Policy Changes
January 27, 2025
A comprehensive commentary by the Medicare Rights Center on the Centers for Medicare & Medicaid Services (CMS) proposed rule for Contract Year 2026 (CMS–4208–P). The document outlines feedback and recommendations on changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and related policies. Topics include consumer protections, health equity, benefit transparency, drug affordability, and the integration of AI in healthcare services. This submission emphasizes safeguarding beneficiary access to affordable, equitable, and transparent healthcare.
Second Set of Part D Drugs for Medicare Negotiation Includes Blockbuster Diabetes and Weight-Loss Drugs
January 23, 2025
On January 17, the U.S. Department of Health and Human Services (HHS) announced the 15 Part D drugs that will
Millions of People With Medicare Drug Coverage to Save With New Cap in 2025
January 16, 2025
A new report from the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE) projects that
Medicare in 2025: Key Changes and Updates
January 9, 2025
Annual changes to premiums and cost-sharing, as well as the continued rollout of significant Part D reforms included in the
Negotiated Prices Take Effect for Ten Drugs in 2026
October 9, 2025
The Inflation Reduction Act (IRA) of 2022 created a new ability for Medicare to negotiate prices for the most expensive
Part D Benefit Restructuring Reduces Out-Of-Pocket Exposure, Changes Risk to Prescription Coverage Access and Choice
July 17, 2025
Prescription drug coverage in Medicare, provided via private health insurance plans under Part D, covers more than 53 million Americans.
New Research Confirms Importance of Drug Affordability and Low Out-of-Pocket Costs
April 24, 2025
As we have highlighted in past articles, many people with Medicare—and many callers to our national consumer helpline—struggle to afford
Drug Pricing Executive Order Boosts Pharmaceutical Industry’s Goals
April 17, 2025
On Tuesday, President Trump issued an executive order on prescription drug pricing that supports key drug industry efforts to weaken
Proposed Rule Would Improve Medicare Advantage Prior Authorization and Transparency
January 30, 2025
This week, Medicare Rights submitted comments in response to the annual Medicare Advantage (MA) and Part D proposed rule for
Comments on Proposed 2026 Medicare Advantage Part D Policy Changes
January 27, 2025
A comprehensive commentary by the Medicare Rights Center on the Centers for Medicare & Medicaid Services (CMS) proposed rule for Contract Year 2026 (CMS–4208–P). The document outlines feedback and recommendations on changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and related policies. Topics include consumer protections, health equity, benefit transparency, drug affordability, and the integration of AI in healthcare services. This submission emphasizes safeguarding beneficiary access to affordable, equitable, and transparent healthcare.
Second Set of Part D Drugs for Medicare Negotiation Includes Blockbuster Diabetes and Weight-Loss Drugs
January 23, 2025
On January 17, the U.S. Department of Health and Human Services (HHS) announced the 15 Part D drugs that will
Millions of People With Medicare Drug Coverage to Save With New Cap in 2025
January 16, 2025
A new report from the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE) projects that
Medicare in 2025: Key Changes and Updates
January 9, 2025
Annual changes to premiums and cost-sharing, as well as the continued rollout of significant Part D reforms included in the